KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.

BMC Cancer · 2013 · PMC4015926 · PMID 24139521

Europe PMC DOI

hedged sentence

0.0570

closest p · 1.1× alpha

0.0570

boldest claim

The sentences

showed a trendp = 0,057so close (0.05 < p ≤ 0.1)

BRAF mutated implants showed a trend (p = 0,057) of higher overall p16 immunoreactivity though no such relation was observed for p53.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.